Vexxa Lifesciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Vexxa Lifesciences Private Limited Pharmaceutical Export Portfolio Dataset — 11 Products, $3.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Vexxa Lifesciences Private Limited — Pharmaceutical Exporter Profile (2026) | 11 Products, $3.5M Trade | TransData Nexus

Who is Vexxa Lifesciences Private Limited? — Company Overview & Market Position

Vexxa Lifesciences Private Limited is a privately held pharmaceutical company established on November 3, 2011, in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH2011PTC284061. Its authorized capital stands at ₹5.00 crore, with a paid-up capital of ₹2.70 crore. The registered office is located at 401, 4th Floor, Mehta Mahal, 15th Mathew Road, Opera House, Charni Road (East), Mumbai, Maharashtra, 400004.

Vexxa Lifesciences specializes in the development and distribution of generic pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans across three therapeutic categories: Advanced Oncology (58.0%), Oncology (32.2%), and Advanced Antibiotics (9.8%). The top five products contributing to 68.8% of the total export value are Docetaxel ($817K), Capecitabine ($542K), Oxaliplatin ($408K), Imipenem ($348K), and Doxorubicin ($325K).

What Does Vexxa Lifesciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Docetaxel$817.5K 2Capecitabine$541.6K 3Oxaliplatin$408.3K 4Imipenem$348.2K 5Doxorubicin$325.5K 6Erlotinib$290.8K 7Pemetrexed$230.5K 8Imatinib$204.3K 9Letrozole$168.3K 10Bortezomib$166.6K 11Gefitinib$45.6K

Vexxa Lifesciences Private Limited Therapeutic Categories — 3 Specializations

Vexxa Lifesciences Private Limited operates across 3 therapeutic categories, with Advanced Oncology (58.0%), Oncology (32.2%), Advanced Antibiotics (9.8%) representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 69% of total exports.

Advanced Oncology

8 products · 58.0% · $2.1M

Oncology

2 products · 32.2% · $1.1M

Advanced Antibiotics

1 products · 9.8% · $348.2K

Product Portfolio — Top 11 by Export Value

Vexxa Lifesciences Private Limited exports 11 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Docetaxel	Oncology	$817.5K	64	2.1%	11
2	Capecitabine

Key Metrics

Total Trade$3.5M

Products11

Shipments508

Categories3

#1 Rankings0

Top 5 Concentration68.8%

Top Categories

Advanced Oncology58.0%

Oncology32.2%

Advanced Antibiotics9.8%

Last updated: March 28, 2026

Vexxa Lifesciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Vexxa Lifesciences operates manufacturing facilities in Mumbai, Maharashtra, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding plant capacities and certifications are not publicly disclosed.

Buyer Due Diligence Brief — Evaluating Vexxa Lifesciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Vexxa Lifesciences has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $3.5 million USD across 508 shipments. The company's portfolio concentration, with the top five products accounting for 68.8% of the total export value, indicates a focused approach to product offerings. The absence of publicly available records indicating regulatory non-compliance further underscores the company's reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Vexxa Lifesciences as a supplier:

FDA Facility Registration: Confirm the registration status of Vexxa Lifesciences' manufacturing facilities with the U.S. Food and Drug Administration.
WHO-GMP Certification: Verify the validity and scope of the World Health Organization's Good Manufacturing Practice certification.
EU GMP Certification: Ensure the European Union's Good Manufacturing Practice certification is current and applicable to the intended products.
ISO Certifications: Assess the company's adherence to relevant International Organization for Standardization standards.

These certifications can typically be verified through the respective regulatory bodies' official websites or by direct communication with Vexxa Lifesciences.

3Due Diligence Checklist

When conducting due diligence on Vexxa Lifesciences, consider the following steps:

Regulatory Compliance: Review the company's compliance history with regulatory authorities, including any Form 483 observations, warning letters, or import alerts.
Financial Performance: Analyze the company's financial statements to assess revenue growth, profitability, and financial stability.
Product Portfolio: Evaluate the diversity and quality of the company's product offerings, including any proprietary formulations.
Supply Chain Reliability: Assess the consistency and reliability of the company's supply chain, including lead times and delivery performance.
References and Reviews: Seek feedback from existing clients and partners to gauge satisfaction and reliability.

Red flags to watch for include unexplained financial discrepancies, regulatory non-compliance issues, and negative feedback from business partners. Recommended pre-order checks involve verifying product quality through samples, confirming regulatory approvals for the intended markets, and establishing clear communication channels with the company.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Supplier Matching: Vexxa Lifesciences Private Limited identified across shipments using name normalization, aggregating 2 name variants.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
3.Market Share: Calculated per product as Vexxa Lifesciences Private Limited's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 508 individual customs records matching Vexxa Lifesciences Private Limited.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

11 Products Tracked

3 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Vexxa Lifesciences Private Limited

Vexxa Lifesciences Private Limited — Export Portfolio & Destination Treemap

Who is Vexxa Lifesciences Private Limited? — Company Overview & Market Position

What Does Vexxa Lifesciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

Vexxa Lifesciences Private Limited Therapeutic Categories — 3 Specializations

Product Portfolio — Top 11 by Export Value

Key Metrics

Top Categories

Vexxa Lifesciences Private Limited — Corporate Profile & Information

1Corporate Overview

2Manufacturing Facilities

Top Export Routes

Related Analysis

Need Detailed Data?

3Key Leadership

Where Does Vexxa Lifesciences Private Limited Export? — Destination Intelligence

1Regulated Markets

2Emerging Markets

3Geographic Strategy

Vexxa Lifesciences Private Limited — Manufacturing & Regulatory Profile

1FDA Status

2WHO & EU GMP

3CDSCO & Indian Regulatory

4Recent Regulatory Actions

Vexxa Lifesciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

1Competitive Landscape

2Key Differentiators

3Strategic Position

Buyer Due Diligence Brief — Evaluating Vexxa Lifesciences Private Limited as a Supplier

1Supplier Assessment

2Certifications to Verify

3Due Diligence Checklist

Frequently Asked Questions — Vexxa Lifesciences Private Limited

How many pharmaceutical products does Vexxa Lifesciences Private Limited export from India?

What is Vexxa Lifesciences Private Limited's total pharmaceutical export value?

What therapeutic categories does Vexxa Lifesciences Private Limited cover?

Get Full Vexxa Lifesciences Private Limited Export Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology